Kamil Wolyniec
Overview
Explore the profile of Kamil Wolyniec including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
205
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wolyniec K, OCallaghan C, Fisher K, Jessica S, Tothill R, Bowtell D, et al.
Psychooncology
. 2023 Jan;
32(4):589-596.
PMID: 36690922
Objective: Patients with Cancer of Unknown Primary (CUP) commonly report poor understanding of their illness and high levels of psychological distress. Despite the potential benefits to CUP patients, there is...
2.
Wolyniec K, Sharp J, Fisher K, Tothill R, Bowtell D, Mileshkin L, et al.
Psychooncology
. 2022 Jun;
31(11):1869-1876.
PMID: 35765251
Objective: Patients diagnosed with Cancer of Unknown Primary (CUP) experience high levels of psychological distress and report poor understanding of their cancer. We aimed to investigate: (1) if CUP patients...
3.
Wolyniec K, Sharp J, Lazarakis S, Mileshkin L, Schofield P
Psychooncology
. 2020 Feb;
29(4):632-638.
PMID: 32026561
Objective: To systematically review literature exploring experiences of cancer patients regarding their understanding of treatment-focused genomic testing as well as their information needs and related themes. Methods: Six databases were...
4.
Cater M, Materia S, Xiao Z, Wolyniec K, Ackland S, Yap Y, et al.
Biometals
. 2014 May;
27(4):661-72.
PMID: 24816595
Glutaredoxin1 (GRX1) is a glutathione (GSH)-dependent thiol oxidoreductase. The GRX1/GSH system is important for the protection of proteins from oxidative damage and in the regulation of protein function. Previously we...
5.
Wolyniec K, Carney D, Haupt S, Haupt Y
Front Oncol
. 2013 Jun;
3:124.
PMID: 23730625
The tumor suppressor function of the promyelocytic leukemia (PML) protein was first identified as a result of its dysregulation in acute promyelocytic leukemia, however, its importance is now emerging far...
6.
Cater M, Pearson H, Wolyniec K, Klaver P, Bilandzic M, Paterson B, et al.
ACS Chem Biol
. 2013 May;
8(7):1621-31.
PMID: 23656859
The therapeutic efficacy of two bis(thiosemicarbazonato) copper complexes, glyoxalbis[N4-methylthiosemicarbazonato]Cu(II) [Cu(II)(gtsm)] and diacetylbis[N4-methylthiosemicarbazonato]Cu(II) [Cu(II)(atsm)], for the treatment of prostate cancer was assessed in cell culture and animal models. Distinctively, copper dissociates...
7.
Wolyniec K, Chan A, Haupt S, Haupt Y
Cell Cycle
. 2012 Sep;
11(20):3705-6.
PMID: 22983003
No abstract available.
8.
Wolyniec K, Shortt J, de Stanchina E, Levav-Cohen Y, Alsheich-Bartok O, Louria-Hayon I, et al.
Blood
. 2012 Jun;
120(4):822-32.
PMID: 22689861
Neoplastic transformation requires the elimination of key tumor suppressors, which may result from E3 ligase-mediated proteasomal degradation. We previously demonstrated a key role for the E3 ubiquitin ligase E6AP in...
9.
Zuckerman V, Wolyniec K, Sionov R, Haupt S, Haupt Y
J Pathol
. 2009 Jun;
219(1):3-15.
PMID: 19562738
p53 is regarded as a central player in tumour suppression, as it controls programmed cell death (apoptosis) as well as cellular senescence. While apoptosis eliminates cells at high risk for...